tomivosertib: Clinical Trials

7 trials of tomivosertib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 terminated, 2 completed, 1 unknown. 7 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Terminated 4, Completed 2, Unknown 1
Phase 12Terminated 2

Follow tomivosertib: new trials by email Literature Review of tomivosertib trials Research Report on tomivosertib

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
Tomivosertib, Pembrolizumab, Pemetrexed - Non-small Cell Lung Cancer
Phase 2UnknownEffector Therapeutics682021-06-022024-04-30
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
eFT508 - Castrate-resistant Prostate Cancer (CRPC)
Phase 2TerminatedEffector Therapeutics162018-11-272024-06-21
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Tomivosertib (eFT-508) - Solid Tumors
Phase 2CompletedEffector Therapeutics392018-07-252023-03-22
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
eFT508 - Triple Negative Breast Cancer, Hepatocellular Carcinoma
Phase 2TerminatedEffector Therapeutics32017-11-212019-07-18
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
eFT508, Avelumab - Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Phase 2CompletedEffector Therapeutics562017-09-182019-07-18
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Tomivosertib (eFT-508) - Lymphoma
Phase 1 / Phase 2TerminatedEffector Therapeutics282017-02-082020-11-02
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
eFT508 - Cancer
Phase 1 / Phase 2TerminatedEffector Therapeutics662015-12-032020-11-02

Conditions studied

Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Lymphoma (1)  ·  Melanoma (1)  ·  Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Thyroid Diseases (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Effector Therapeutics (7)

Countries

United States (7)  ·  Australia (1)  ·  Georgia (1)

Top investigators

Jeremy Barton, MD (4)  ·  Douglas Warner, MD (1)  ·  Lyon Gleich, MD (1)  ·  Lyon Gliech, MD (1)

Results publications

PMID 34187739, PMID 37694854